Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
Conclusion: Del19 and L858R have distinct prognostic implications and may require individual therapeutic strategies.Chemotherapy 2017;62:151-158
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva